{"disease":{"id":"multiple-myeloma-in-relapse","name":"multiple myeloma in relapse"},"drugs":{"marketed":[{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02970747","title":"Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients","phase":"","overall_status":"COMPLETED","enrollment_count":359,"lead_sponsor_name":"iOMEDICO AG","has_results":false},{"nct_id":"NCT05495620","title":"Long-term KRd in Relapsed and/or Refractory Multiple Myeloma","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Dong-A University Hospital","has_results":false},{"nct_id":"NCT03952091","title":"TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":289,"lead_sponsor_name":"TJ Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT06119685","title":"IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":128,"lead_sponsor_name":"Indapta Therapeutics, INC.","has_results":false},{"nct_id":"NCT04603872","title":"CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT03860038","title":"TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"TJ Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT04063189","title":"Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple Myeloma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"The First Hospital of Jilin University","has_results":false},{"nct_id":"NCT07096778","title":"Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"CellCentric Ltd.","has_results":false},{"nct_id":"NCT04184050","title":"Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":false},{"nct_id":"NCT04287855","title":"Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":82,"lead_sponsor_name":"Poitiers University Hospital","has_results":false},{"nct_id":"NCT04271644","title":"BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT04776330","title":"a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT04790474","title":"Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":61,"lead_sponsor_name":"Tel-Aviv Sourasky Medical Center","has_results":false},{"nct_id":"NCT07032129","title":"Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Essen Biotech","has_results":false},{"nct_id":"NCT03428373","title":"Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":57,"lead_sponsor_name":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","has_results":false},{"nct_id":"NCT04094961","title":"Ixazomib + Pomalidomide + Dexamethasone In MM","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":52,"lead_sponsor_name":"Omar Nadeem, MD","has_results":false},{"nct_id":"NCT07200089","title":"Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":52,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT06880601","title":"Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":52,"lead_sponsor_name":"Gruppo Italiano Malattie EMatologiche dell'Adulto","has_results":false},{"nct_id":"NCT07191379","title":"Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Odense University Hospital","has_results":false},{"nct_id":"NCT05909826","title":"Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":49,"lead_sponsor_name":"Dong-A University Hospital","has_results":false},{"nct_id":"NCT05581875","title":"A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Hellenic Society of Hematology","has_results":false},{"nct_id":"NCT06255847","title":"Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMM","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":43,"lead_sponsor_name":"Shanxi Bethune Hospital","has_results":false},{"nct_id":"NCT04272151","title":"Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT03697629","title":"A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Canadian Myeloma Research Group","has_results":false},{"nct_id":"NCT06846905","title":"Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.","phase":"","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"University Hospital, Toulouse","has_results":false},{"nct_id":"NCT06115135","title":"A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":39,"lead_sponsor_name":"Oncotherapeutics","has_results":false},{"nct_id":"NCT02103335","title":"Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT04657861","title":"APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT03136653","title":"A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Molecular Partners AG","has_results":false},{"nct_id":"NCT04065308","title":"Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":33,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT03777410","title":"Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma","phase":"","overall_status":"TERMINATED","enrollment_count":33,"lead_sponsor_name":"Travera Inc","has_results":false},{"nct_id":"NCT03650491","title":"A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Fortis Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06225310","title":"A Trial of Selinexor, Ruxolitinib and Methylprednisolone","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Oncotherapeutics","has_results":false},{"nct_id":"NCT05546723","title":"LMY-920 for Treatment of Relapsed or Refractory Myeloma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Luminary Therapeutics","has_results":false},{"nct_id":"NCT06822972","title":"HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":27,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT04688853","title":"A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":26,"lead_sponsor_name":"Gadeta B.V.","has_results":false},{"nct_id":"NCT06158412","title":"All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"The First Affiliated Hospital of Xiamen University","has_results":false},{"nct_id":"NCT03030261","title":"Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":25,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT07421856","title":"Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":24,"lead_sponsor_name":"Hebei Senlang Biotechnology Inc., Ltd.","has_results":false},{"nct_id":"NCT07456605","title":"Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT03672253","title":"CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Second Affiliated Hospital of Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT03601624","title":"Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":18,"lead_sponsor_name":"Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado","has_results":false},{"nct_id":"NCT04861480","title":"Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":18,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT05739188","title":"Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":18,"lead_sponsor_name":"920th Hospital of Joint Logistics Support Force of People's Liberation Army of China","has_results":false},{"nct_id":"NCT05020444","title":"TriPRIL CAR T Cells in Multiple Myeloma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Marcela V. Maus, M.D.,Ph.D.","has_results":false},{"nct_id":"NCT03155100","title":"Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Raija Silvennoinen","has_results":false},{"nct_id":"NCT03266692","title":"Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":15,"lead_sponsor_name":"Cogent Biosciences, Inc.","has_results":false},{"nct_id":"NCT02722668","title":"UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":true},{"nct_id":"NCT03702725","title":"Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Alliance Foundation Trials, LLC.","has_results":true},{"nct_id":"NCT05121103","title":"A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"Epizyme, Inc.","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}